基准维持大麻公司Schwazze的“买”评级,目标价格为2.50美元。 Benchmark maintains "buy" rating for cannabis firm Schwazze with a $2.50 target price.

投资公司Benchmark再次确认其"购买"评级为医学人技术 (SHWZ), 设定目标价格为2.50美元. Investment firm Benchmark has reaffirmed its "buy" rating for Medicine Man Technologies (SHWZ), setting a target price of $2.50. 该公司以Schwazze为经营单位,从事零售、批发和大麻业的其他部门。 The company, operating as Schwazze, is involved in retail, wholesale, and other segments of the cannabis industry. 随着52周高点为1.55美元和52周低点为0.01美元, 基准的持续支持突显了他们对行业增长潜力的信心. With a 52-week high of $1.55 and a 52-week low of $0.01, Benchmark's ongoing support highlights their confidence in the industry's growth potential.